Compare GSK plc (GSK) vs Vanguard Value Index Fund ETF (VTV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Vanguard Value Index Fund ETF — how do they compare? GSK plc trades at $46.64 (market cap $91.88B), while Vanguard Value Index Fund ETF trades at $220.49 (market cap $262.40B). The key difference: Vanguard Value Index Fund ETF is far larger — about 2.9× GSK plc's market cap, and GSK plc pays a 3.9% dividend while Vanguard Value Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Vanguard Value Index Fund ETF for 142 Days on average.
| GSK | VTV | |
|---|---|---|
Market Cap | $91.88B | $262.40B |
Volume | 7,730,529 | 3,293,281 |
Sector | Health | — |
52-Week High | $61.18 | $227.51 |
52-Week Low | $43.24 | $182.86 |
Typical Hold Time | 93 Days | 142 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
VTV trades at $220.55, up 1.07% with a bearish technical signal despite bullish moving averages. The ETF shows institutional accumulation with recent purchases by QRG Capital Management and Blue Edge Capital. Recent news highlights value stocks outperforming growth in 2026, with VTV's 2.3% yield and low 0.03% fee attracting income-focused investors amid market rotation from tech.
The outlook remains mixed—technical indicators suggest near-term pressure, but strong institutional interest and value stock momentum support long-term stability. Key risks include underperformance versus broad market indices and sensitivity to interest rate changes. The dividend yield provides income cushion, yet investors should weigh VTV's value tilt against broader market exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →
